{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T11:11:24Z","timestamp":1785669084867,"version":"3.56.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.clinthera.2010.01.014","type":"journal-article","created":{"date-parts":[[2010,2,18]],"date-time":"2010-02-18T09:27:14Z","timestamp":1266485234000},"page":"179-192","source":"Crossref","is-referenced-by-count":31,"title":["Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study"],"prefix":"10.1016","volume":"32","author":[{"given":"Manuel","family":"Vaz-da-Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amilcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Soares-da-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2010.01.014_bib1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1528-1167.2008.01946.x","article-title":"Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, doubleblind, placebo-controlled, parallel-group phase III study","volume":"50","author":"Elger","year":"2009","journal-title":"Epilepsia."},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2010.01.014_bib2","first-page":"104","article-title":"Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-302 study","volume":"50","author":"Hufnagel","year":"2009","journal-title":"Epilepsia."},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2010.01.014_bib3","first-page":"106","article-title":"Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-303 study","volume":"50","author":"Lopes-Lima","year":"2009","journal-title":"Epilepsia."},{"key":"10.1016\/j.clinthera.2010.01.014_bib4","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1177\/0091270005279364","article-title":"Single-dose and steadystate pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects","volume":"45","author":"Almeida","year":"2005","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2010.01.014_bib5","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.nurt.2006.10.005","article-title":"Eslicarbazepine acetate (BIA 2-093)","volume":"4","author":"Almeida","year":"2007","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.clinthera.2010.01.014_bib6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1528-1167.2007.00984.x","article-title":"Eslicarbazepine acetate: A doubleblind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures","volume":"48","author":"Elger","year":"2007","journal-title":"Epilepsia."},{"issue":"Suppl","key":"10.1016\/j.clinthera.2010.01.014_bib7","doi-asserted-by":"crossref","first-page":"22S","DOI":"10.1378\/chest.119.1_suppl.22S","article-title":"Managing oral anticoagulant therapy","volume":"119","author":"Ansell","year":"2001","journal-title":"Chest."},{"key":"10.1016\/j.clinthera.2010.01.014_bib8","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/clpt.1994.139","article-title":"Stereochemical aspects of warfarin drug interactions: Use of a combined pharmacokineticpharmacodynamic model","volume":"56","author":"Chan","year":"1994","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2010.01.014_bib9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/cpt1976195part1552","article-title":"Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect","volume":"19","author":"Yacobi","year":"1976","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2010.01.014_bib10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1592\/phco.21.2.235.34106","article-title":"Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing","volume":"21","author":"Redman","year":"2001","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.clinthera.2010.01.014_bib11","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/j.1875-9114.1997.tb03782.x","article-title":"A review of enzyme induction of warfarin metabolism with recommendations for patient management","volume":"17","author":"Cropp","year":"1997","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.clinthera.2010.01.014_bib12","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2165\/00002018-199309030-00003","article-title":"Antiepileptic drugs. A review of clinically significant drug interactions","volume":"9","author":"Patsalos","year":"1993","journal-title":"Drug Saf."},{"key":"10.1016\/j.clinthera.2010.01.014_bib13","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/cpt1971123539","article-title":"Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man","volume":"12","author":"Hansen","year":"1971","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2010.01.014_bib14","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1136\/bmj.280.6229.1415-a","article-title":"Interaction between carbamazepine and warfarin","volume":"280","author":"Ross","year":"1980","journal-title":"Br MedJ."},{"key":"10.1016\/j.clinthera.2010.01.014_bib15","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-94-2-280_1","article-title":"Warfarincarbamazepine interaction","volume":"94","author":"Kendall","year":"1981","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.clinthera.2010.01.014_bib16","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ana.410130629","article-title":"Effect of carbamazepine on Coumadin metabolism","volume":"13","author":"Massey","year":"1983","journal-title":"Ann Neurol."},{"key":"10.1016\/j.clinthera.2010.01.014_bib17","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1097\/00007611-199008000-00033","article-title":"Clinically significant hemorrhage due to war- farin-carbamazepine interaction","volume":"83","author":"Denbow","year":"1990","journal-title":"South MedJ."},{"key":"10.1016\/j.clinthera.2010.01.014_bib18","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/0006-2952(94)90071-X","article-title":"Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation","volume":"47","author":"Kerr","year":"1994","journal-title":"Biochem Pharmacol."},{"key":"10.1016\/j.clinthera.2010.01.014_bib19","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00228-006-0104-4","article-title":"The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose","volume":"62","author":"Herman","year":"2006","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2010.01.014_bib22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2165\/00126839-200304050-00001","article-title":"Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans","volume":"4","author":"Almeida","year":"2003","journal-title":"Drugs R D."},{"key":"10.1016\/j.clinthera.2010.01.014_bib23","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1177\/0091270004267591","article-title":"Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multipledose study in young healthy humans","volume":"44","author":"Almeida","year":"2004","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2010.01.014_bib24","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00126839-200506050-00001","article-title":"Eslicarbazepine acetate (BIA 2-093): Relative bioavailability and bioequivalence of 50 mg\/mL oral suspension and 200mg and 800mg tablet formulations","volume":"6","author":"Fontes-Ribeiro","year":"2005","journal-title":"Drugs R D."},{"key":"10.1016\/j.clinthera.2010.01.014_bib25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/00126839-200506040-00002","article-title":"Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093)","volume":"6","author":"Maia","year":"2005","journal-title":"Drugs R D."},{"key":"10.1016\/j.clinthera.2010.01.014_bib27","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0731-7085(00)00232-6","article-title":"Validation of a method for the determination of (R)-warfarin and (S)-warfarin in human plasma using LC with UV detection","volume":"22","author":"Ring","year":"2000","journal-title":"J Pharm Biomed Anal."},{"key":"10.1016\/j.clinthera.2010.01.014_bib30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF01065653","article-title":"Population pharmacokinetics of racemic warfarin in adult patients","volume":"13","author":"Mungall","year":"1985","journal-title":"J Pharmacokinet Biopharm."},{"key":"10.1016\/j.clinthera.2010.01.014_bib31","first-page":"427","article-title":"Reference tables for the intrasubject coefficient of variation in bioequivalence studies","volume":"33","author":"Steinijans","year":"1995","journal-title":"Int J Clin Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2010.01.014_bib32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/0091270004271404","article-title":"Interaction of warfarin with drugs, natural substances, and foods","volume":"45","author":"Greenblatt","year":"2005","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2010.01.014_bib33","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00228-007-0414-1","article-title":"Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment","volume":"64","author":"Almeida","year":"2008","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2010.01.014_bib34","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1021\/js9600134","article-title":"Protein-binding highperformance frontal analysis of (R)-and (S)-warfarin on HSA with and without phenylbutazone","volume":"86","author":"He","year":"1997","journal-title":"J Pharm Sci."},{"key":"10.1016\/j.clinthera.2010.01.014_bib35","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/MBC.0b013e3280444bfd","article-title":"Plasma S\/R ratio of warfarin covaries with VKORC1 haplotype","volume":"18","author":"Osman","year":"2007","journal-title":"Blood Coagul Fibrinolysis."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810000159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810000159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T03:44:19Z","timestamp":1711251859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291810000159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0149291810000159"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2010.01.014","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}